Evidence map›Paper›PMID 33959609›Full record

ReviewFrontiers in cell and developmental biology2021

Chromatin Imbalance as the Vertex Between Fetal Valproate Syndrome and Chromatinopathies.

Chiara Parodi, Elisabetta Di Fede, Angela Peron, Ilaria Viganò, Paolo Grazioli, Silvia Castiglioni, Richard H Finnell, Cristina Gervasini, Aglaia Vignoli, Valentina Massa

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Chiara ParodiDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Elisabetta Di FedeDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Angela PeronHuman Pathology and Medical Genetics, ASST Santi Paolo e Carlo, San Paolo Hospital, Milan, Italy.
Ilaria ViganòDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Paolo GrazioliDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Silvia CastiglioniDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Richard H FinnellDepartments of Molecular and Cellular Biology, Molecular and Human Genetics and Medicine, Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, United States.
Cristina GervasiniDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Aglaia VignoliDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Valentina MassaDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
University of Milan · ITAzienda Socio Sanitaria Territoriale Santi Paolo e CarloBaylor College of Medicine · US

Funding

Translational Research Support CoreP30ES030285 · NIEHS · BAYLOR COLLEGE OF MEDICINE · PI Casey W Wright · 2019 to 2026
$14.7M
NIEHS NIH HHS P30 ES030285
6 · The paper itself

Abstract

Prenatal exposure to valproate (VPA), an antiepileptic drug, has been associated with fetal valproate spectrum disorders (FVSD), a clinical condition including congenital malformations, developmental delay, intellectual disability as well as autism spectrum disorder, together with a distinctive facial appearance. VPA is a known inhibitor of histone deacetylase which regulates the chromatin state. Interestingly, perturbations of this epigenetic balance are associated with chromatinopathies, a heterogeneous group of Mendelian disorders arising from mutations in components of the epigenetic machinery. Patients affected from these disorders display a plethora of clinical signs, mainly neurological deficits and intellectual disability, together with distinctive craniofacial dysmorphisms. Remarkably, critically examining the phenotype of FVSD and chromatinopathies, they shared several overlapping features that can be observed despite the different etiologies of these disorders, suggesting the possible existence of a common perturbed mechanism(s) during embryonic development.

Indexed as

anti-epileptic drugschromatinopathiesfetal valproate syndromeHDAC inhibitorneurodevelopment

Identifiers

PMID33959609
PMCPMC8093873
OpenAlexW3153259763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.